CV
CapsoVision, Inc. NASDAQ Listed Sep 3, 2001$7.17
+8.97%
vs $6.58
Mkt Cap $1.8B
52w Low $3.56
33.2% of range
52w High $14.42
50d MA $6.78
200d MA $6.63
P/E (TTM)
-6.8x
EV/EBITDA
—
P/B
132.8x
Debt/Equity
0.1x
ROE
-190.9%
P/FCF
-76.7x
RSI (14)
68.70
ATR (14)
$0.33
Beta
-4.12
50d MA
$6.78
200d MA
$6.63
Avg Volume
178.9K
Medical‑technology company developing advanced capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and AI-enabled imaging platforms for gastrointestinal diagnostics
CIK (SEC)
Phone
14086241488
Cox Avenue · Saratoga, CA 95070 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.17 | -0.16 | +5.9% | 7.53 | -9.2% | -0.3% | -4.7% | +1.8% | -8.8% | +11.9% | — |
| Nov 13, 2025 | AMC | -0.14 | -0.17 | -21.4% | 5.67 | -8.1% | -9.7% | +3.1% | +4.2% | -3.1% | +0.0% | — |
| Aug 14, 2025 | AMC | -0.11 | -2.02 | -1736.4% | 4.02 | -2.2% | -4.2% | +3.9% | -2.8% | +1.3% | +1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $7.53 | $6.84 | -9.2% | -0.3% | -4.7% | +1.8% | -8.8% | +11.9% |
| Dec 31 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $12.39 | $12.48 | +0.7% | -13.7% | -4.2% | -17.1% | -6.4% | -5.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 17, 2026 | HARARI ELIYAHOU ET AL10% | — | Buy | 61,068 | $6.73 | $411K | 3,343,119 | -1.57% | +0.15% |
| Jun 26, 2026 | HARARI ELIYAHOU ET AL10% | — | Buy | 13,850 | $7.35 | $102K | 3,200,751 | +8.11% | +2.25% |
| Jun 8, 2026 | Imperial Joanne CarolDir | — | Sell | 1,200 | $7.16 | $9K | 1,687 | -1.22% | -5.87% |
8-K · 7.01
! Medium
CapsoVision, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jul 2
8-K
CapsoVision, Inc. -- 8-K Filing
Jun 12
8-K
Unknown — 8-K Filing
CV's 13% YoY revenue growth to $3.9M signals commercialization progress, but investors should monitor whether this early-stage medtech can reach profitability before cash depletion threatens viability.
Mar 26
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
CV's equity issuance dilutes existing shareholders' ownership and may pressure the stock price, though the capital raised likely funds operations or strategic initiatives.
Mar 20
8-K
Unknown — 8-K Filing
Cogent Inc's development costs for Canon partnership rose $1 million due to enhanced specifications, reducing near-term profitability but potentially positioning the product for stronger market acceptance and revenue generation.
Mar 13
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 1,026,269 | $7M | New | Mar 2026 |
| 2 | Vanguard Portfolio Management Llc | 164,386 | $1M | New | Mar 2026 |
| 3 | Northern Trust Corp | 152,334 | $1M | Added | Mar 2026 |
| 4 | Ubs Group Ag | 65,156 | $475K | Added | Mar 2026 |
| 5 | Bank Of New York Mellon Corp | 49,294 | $359K | New | Mar 2026 |
| 6 | Nuveen, Llc | 33,098 | $241K | New | Mar 2026 |
| 7 | Morgan Stanley | 18,926 | $202K | Reduced | Dec 2025 |
| 8 | Bank Of America Corp /de/ | 22,238 | $162K | Added | Mar 2026 |
| 9 | Susquehanna International Group, Llp | 17,645 | $129K | New | Mar 2026 |
| 10 | Alaska Wealth Advisors, Llc | 11,093 | $119K | New | Dec 2025 |
| 11 | Barclays Plc | 11,866 | $87K | Added | Mar 2026 |
| 12 | Jpmorgan Chase & Co | 11,318 | $81K | Added | Mar 2026 |
| 13 | Wells Fargo & Company/mn | 10,245 | $75K | New | Mar 2026 |
| 14 | Bnp Paribas Financial Markets | 6,103 | $44K | Added | Mar 2026 |
| 15 | Russell Investments Group, Ltd. | 2,206 | $16K | Added | Mar 2026 |
| 16 | California State Teachers Retirement System | 1,527 | $11K | New | Mar 2026 |
| 17 | Fmr Llc | 1,161 | $8K | Added | Mar 2026 |
| 18 | Cwm, Llc | 53 | $386 | Added | Mar 2026 |
| 19 | Arax Advisory Partners | 1 | $7 | New | Mar 2026 |
| 20 | Royal Bank Of Canada | 31 | — | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.76B
Enterprise Value
$1.75B
P/E (TTM)
-6.83x
Forward P/E
—
PEG Ratio
-1.06x
P/B
132.78x
P/S
129.81x
P/FCF
-76.70x
EV/EBITDA
—
Shares Out
245.6M
Financials (TTM)
Revenue
$13.6M
Net Income
-$27.0M
EBITDA
-$26.6M
Free Cash Flow
-$23.0M
Op Cash Flow
-$22.9M
EPS Basic
$-1.03
EPS Diluted
$-1.05
EPS Forward
$-0.48
Gross Margin
51.7%
Op Margin
-11.0%
Net Margin
-198.9%
Balance Sheet
Total Assets
$18.2M
Total Liab.
$4.9M
Total Equity
$13.3M
Cash
$10.1M
LT Debt
$0
Book Value/Sh
$0.05
Debt/Equity
0.07x
Current Ratio
3.77
Quick Ratio
3.09
Returns & Growth
ROE
-190.9%
ROA
-139.4%
ROIC
1.6%
Rev Growth YoY
+15.3%
EPS Growth YoY
-98.1%
Price Returns
2W
-1.9%
1M
-10.7%
3M
-12.3%
6M
+31.1%
12M
+68.3%
Technicals
52W High
$14.42
52W Low
$3.56
50d MA
$6.78
200d MA
$6.63
RSI (14)
68.70
ATR (14)
$0.33
Beta
-4.12
Avg Volume
179K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
4
Ex-Div Date
May 2, 2012
Analyst Price Targets
Consensus
$7.00
High
$7.00
Low
$7.00
Median
$7.00
Data updated apr 25, 2026 4:01am
· Source: financialmodelingprep.com